A Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy in Patients With Atrial Fibrillation

Registry ID
NCT07762742
Source registry
NCT
Status
NOT_YET_RECRUITING
Phase
NA
Study type
INTERVENTIONAL
Sponsor
China National Center for Cardiovascular Diseases
Enrollment
276
Start date
2026-08-15
Completion date
2029-02-28
Last update
2026-08-13

Conditions

Summary

This prospective, randomized, multicenter, open-label, non-inferiority interventional study aims to compare the therapeutic efficacy of percutaneous pulsed field ablation (PFA) guided by ultrasound alone versus fluoroscopy in patients with paroxysmal atrial fibrillation (AF). The success rate of complete electrical isolation of pulmonary veins during the procedure was compared to verify that ultrasound-only guidance is non-inferior to fluoroscopic guidance.

Interventions

Inclusion criteria

Inclusion Criteria: * Adult patients aged 18 to 75 years (including 18 years and 75 years of age). * Patients diagnosed with paroxysmal atrial fibrillation via 12-lead electrocardiography or ambulatory electrocardiography and scheduled to undergo pulsed field ablation. * Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.

Exclusion criteria

Exclusion Criteria: * Atrial fibrillation secondary to electrolyte imbalance, thyroid disorders, or reversible non-cardiac causes; * Previous history of catheter ablation or cardiac surgery for atrial fibrillation; * Prior surgical history including patent foramen ovale closure, atrial septal defect closure or repair; * Implantation of left atrial appendage occluder, mechanical mitral valve prosthesis, or valvuloplasty ring containing metallic materials; * Concomitant other tachyarrhythmias requiring catheter ablation (e.g., atrioventricular reentrant tachycardia, atrioventricular nodal reentrant tachycardia, atrial tachycardia, atrial flutter, Wolff-Parkinson-White syndrome, etc.); * Persistent atrial fibrillation; * Left atrial anteroposterior diameter (LAD) \> 55 mm on transthoracic echocardiography; * Women who are pregnant, breastfeeding, or of childbearing age with plans to become pregnant during the clinical trial; * Current participation in another pharmaceutical or medical device clinical study.

Primary outcomes

[{"measure":"Success rate of complete electrical isolation of pulmonary veins during the procedure","timeFrame":"Immediately post-procedure"}]

Related clinical trials

View on source registry